Atlas Trials

Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

Clinical trial NCT03602638 · UNKNOWN

Trial details

NCT number
NCT03602638
Sponsor
Chinese PLA General Hospital
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1
Start date
2018-10-01
Primary completion
2019-05-01
Enrollment
300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.